Arteris Inc
NASDAQ:AIP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Arteris Inc
NASDAQ:AIP
|
US |
|
Aixtron SE
XETRA:AIXA
|
DE |
|
Chengdu Hi-tech Development Co Ltd
SZSE:000628
|
CN |
|
T
|
T-Mobile US Inc
SWB:TM5
|
US |
|
C
|
Compagnia Dei Caraibi SpA
MIL:1TIME
|
IT |
|
KIOCL Ltd
NSE:KIOCL
|
IN |
|
H
|
Hengyuan Refining Company Bhd
KLSE:HENGYUAN
|
MY |
|
G
|
Goldeneye Resources Corp
XTSX:GOE
|
CA |
|
F
|
Fabrinet
SWB:FAN
|
US |
|
Q
|
Quintain Steel Co Ltd
TWSE:2017
|
TW |
|
Auxly Cannabis Group Inc
TSX:XLY
|
CA |
|
Tomoku Co Ltd
TSE:3946
|
JP |
|
D
|
Drugs Made In America Acquisition Corp
NASDAQ:DMAA
|
US |
|
O
|
Oriental Precision & Engineering Co Ltd
KOSDAQ:014940
|
KR |
|
Transgene SA
PAR:TNG
|
FR |
|
Cantor Equity Partners Inc
NASDAQ:CEP
|
US |
|
Miliboo SA
PAR:ALMLB
|
FR |
Income Statement
Earnings Waterfall
Arteris Inc
Income Statement
Arteris Inc
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
38
N/A
|
32
-15%
|
47
+46%
|
51
+8%
|
50
0%
|
52
+3%
|
52
0%
|
52
+1%
|
54
+3%
|
53
0%
|
53
0%
|
55
+3%
|
58
+5%
|
61
+6%
|
63
+3%
|
66
+4%
|
71
+7%
|
|
| Gross Profit | ||||||||||||||||||
| Cost of Revenue |
(4)
|
(3)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(5)
|
(5)
|
(5)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(7)
|
(7)
|
|
| Gross Profit |
34
N/A
|
29
-15%
|
43
+46%
|
46
+8%
|
46
0%
|
47
+3%
|
47
0%
|
48
+1%
|
49
+2%
|
48
-1%
|
48
-1%
|
49
+3%
|
52
+6%
|
55
+7%
|
57
+3%
|
59
+4%
|
64
+7%
|
|
| Operating Income | ||||||||||||||||||
| Operating Expenses |
(56)
|
(48)
|
(67)
|
(73)
|
(75)
|
(78)
|
(82)
|
(83)
|
(84)
|
(84)
|
(82)
|
(83)
|
(83)
|
(85)
|
(88)
|
(91)
|
(97)
|
|
| Selling, General & Administrative |
(25)
|
(20)
|
(29)
|
(32)
|
(34)
|
(35)
|
(37)
|
(38)
|
(39)
|
(39)
|
(39)
|
(39)
|
(38)
|
(39)
|
(40)
|
(43)
|
(47)
|
|
| Research & Development |
(31)
|
(27)
|
(38)
|
(41)
|
(41)
|
(43)
|
(45)
|
(45)
|
(45)
|
(45)
|
(43)
|
(44)
|
(45)
|
(46)
|
(47)
|
(48)
|
(50)
|
|
| Operating Income |
(22)
N/A
|
(18)
+15%
|
(24)
-29%
|
(27)
-14%
|
(29)
-7%
|
(31)
-7%
|
(34)
-10%
|
(35)
-2%
|
(35)
-1%
|
(36)
-1%
|
(34)
+3%
|
(34)
+2%
|
(32)
+6%
|
(30)
+5%
|
(31)
-3%
|
(32)
-3%
|
(33)
-4%
|
|
| Pre-Tax Income | ||||||||||||||||||
| Interest Income Expense |
(1)
|
(0)
|
(0)
|
0
|
1
|
1
|
1
|
1
|
(0)
|
0
|
(1)
|
(1)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
3
|
3
|
3
|
3
|
|
| Pre-Tax Income |
(22)
N/A
|
(19)
+16%
|
(24)
-28%
|
(27)
-11%
|
(28)
-4%
|
(30)
-7%
|
(33)
-11%
|
(34)
-3%
|
(35)
-3%
|
(36)
-1%
|
(34)
+3%
|
(33)
+2%
|
(31)
+7%
|
(30)
+4%
|
(31)
-3%
|
(32)
-3%
|
(33)
-5%
|
|
| Net Income | ||||||||||||||||||
| Tax Provision |
(1)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
1
|
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
(2)
|
(2)
|
(3)
|
(1)
|
|
| Income from Continuing Operations |
(23)
|
(20)
|
(25)
|
(28)
|
(27)
|
(30)
|
(33)
|
(34)
|
(37)
|
(37)
|
(36)
|
(36)
|
(34)
|
(32)
|
(33)
|
(34)
|
(35)
|
|
| Net Income (Common) |
(23)
N/A
|
(20)
+16%
|
(25)
-29%
|
(28)
-11%
|
(27)
+2%
|
(30)
-8%
|
(33)
-12%
|
(34)
-1%
|
(37)
-10%
|
(37)
-1%
|
(36)
+2%
|
(36)
+1%
|
(34)
+6%
|
(32)
+4%
|
(33)
-2%
|
(34)
-4%
|
(35)
-1%
|
|
| EPS (Diluted) |
-1.06
N/A
|
-0.61
+42%
|
-0.78
-28%
|
-0.85
-9%
|
-0.84
+1%
|
-0.85
-1%
|
-0.93
-9%
|
-0.93
N/A
|
-1.03
-11%
|
-0.98
+5%
|
-0.94
+4%
|
-0.91
+3%
|
-0.86
+5%
|
-0.79
+8%
|
-0.79
N/A
|
-0.8
-1%
|
-0.82
-2%
|
|